| Date | Title | Description |
| 18.08.2026 | Elicera Therapeutics appoints Johan Liwing as new CEO | Elicera Therapeutics appoints Johan Liwing as new CEO
Tue, Aug 18, 2026 08:30 CET Report this content
Gothenburg, August 18, 2026 – Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation ca... |
| 06.11.2023 | XNK Therapeutics announces poster presentations at the 38[th] Annual Meeting of the Society for Immunotherapy of Cancer (SITC) | XNK Therapeutics announces poster presentations at the 38[th] Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
Mon, Nov 06, 2023 08:45 CET Report this content
XNK Therapeutics AB (”XNK”) participates in the SITC meeting, whi... |
| 10.10.2023 | XNK Therapeutics receives funding from Sweden’s innovation agency Vinnova | XNK Therapeutics receives funding from Sweden’s innovation agency Vinnova
Tue, Oct 10, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that it has applied for and been granted funding by Sweden’s innovation ag... |
| 27.09.2023 | XNK Therapeutics presented two posters at the NK2023 conference in Oslo | XNK Therapeutics presented two posters at the NK2023 conference in Oslo
Wed, Sep 27, 2023 08:05 CET Report this content
XNK Therapeutics AB today announced that two posters, regarding bladder cancer (BC) and acute myeloid leukemia (AML) res... |
| 28.08.2023 | XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston | XNK Therapeutics to present at the 8th CAR-TCR Summit in Boston
Mon, Aug 28, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that Linda Brick, Head of QA, will be speaking at the 8th CAR-TCR Summit in Boston.
... |
| 24.08.2023 | XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML) | XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)
Thu, Aug 24, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the company has entered... |
| 14.08.2023 | XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September | XNK Therapeutics to present two posters at the NK2023 conference in Oslo in September
Mon, Aug 14, 2023 08:05 CET Report this content
XNK Therapeutics AB today announced that two posters, regarding bladder cancer and Acute Myeloid Leukemia ... |
| 10.08.2023 | XNK Therapeutics enters into agreement with US-based biotechnology company | XNK Therapeutics enters into agreement with US-based biotechnology company
Thu, Aug 10, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the company has entered into an agreement with a US biotechnology co... |
| 07.08.2023 | XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer’s meeting in San Diego in November | XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer’s meeting in San Diego in November
Mon, Aug 07, 2023 09:52 CET Report this content
XNK Therapeutics AB today announced that the abstracts Harnessing the po... |
| 12.07.2023 | XNK Therapeutics one of three winners of Business Sweden’s Catalyst program 2023 | XNK Therapeutics one of three winners of Business Sweden’s Catalyst program 2023
Wed, Jul 12, 2023 08:05 CET Report this content
XNK Therapeutics AB today announced that it has been selected as one of three winners of Business Sweden’s Cata... |
| 07.06.2023 | XNK Therapeutics appoints Hugo Petit as Chief Financial Officer | XNK Therapeutics appoints Hugo Petit as Chief Financial Officer
Wed, Jun 07, 2023 08:05 CET Report this content
XNK Therapeutics today announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and member of the company’s lead... |
| 24.05.2023 | XNK Therapeutics to present at ABG Sundal Collier’s Life Science Summit in Stockholm | XNK Therapeutics to present at ABG Sundal Collier’s Life Science Summit in Stockholm
Wed, May 24, 2023 08:05 CET Report this content
XNK Therapeutics today announced that its CEO Johan Liwing will present at ABG Sundal Collier’s Life Scienc... |
| 04.05.2023 | XNK Therapeutics Enters into Research Agreement with Global Pharma Company | XNK Therapeutics Enters into Research Agreement with Global Pharma Company
Thu, May 04, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the company’s autologous natural killer (NK) cell therapy candidate ... |
| 03.04.2023 | XNK Receives EU Tissue Establishment Certificate | XNK Receives EU Tissue Establishment Certificate
Mon, Apr 03, 2023 08:05 CET Report this content
XNK Therapeutics today announced that it has been approved as an EU Tissue Establishment. This certificate allows the company to take control o... |
| 22.03.2023 | XNK presents at the 8[th] Innate Killer Summit in La Jolla, San Diego | XNK presents at the 8[th] Innate Killer Summit in La Jolla, San Diego
Wed, Mar 22, 2023 08:05 CET Report this content
XNK Therapeutics AB today announced its extensive participation at the 8th Annual Innate Killer Summit in La Jolla, San Di... |
| 20.03.2023 | XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency | XNK receives certificate of GMP compliance of a manufacturer from the Medical Products Agency
Mon, Mar 20, 2023 08:05 CET Report this content
XNK Therapeutics today announced that it has received a GMP manufacturing license and a certificat... |
| 21.02.2023 | XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22 | XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 22
Tue, Feb 21, 2023 08:05 CET Report this content
XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Thera... |
| 19.01.2023 | XNK Therapeutics appoints Dr. Peter Hovstadius as CMO | XNK Therapeutics appoints Dr. Peter Hovstadius as CMO
Thu, Jan 19, 2023 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Peter Hovstadius as Chief Medical Officer (CMO), effective immediately.... |
| 15.12.2022 | First patient cells collected in XNK’s preclinical bladder cancer study | First patient cells collected in XNK’s preclinical bladder cancer study
Thu, Dec 15, 2022 09:49 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the first patient has donated cells in the recently initiated preclinic... |
| 21.11.2022 | XNK Therapeutics continues platform development work with AdBIOPRO after Sweden’s Vinnova extends investment | XNK Therapeutics continues platform development work with AdBIOPRO after Sweden’s Vinnova extends investment
Mon, Nov 21, 2022 09:57 CET Report this content
XNK Therapeutics AB (“XNK”) today said the company would continue its partnership w... |
| 21.11.2022 | XNK Therapeutics continues platform development work with AdBIOPRO after Sweden's Vinnova extends investment | HUDDINGE, Sweden, Nov. 21, 2022 /PRNewswire/ -- XNK Therapeutics AB ("XNK") today said the company would continue its partnership with the Karolinska Cell Therapy Center's production unit Vecura under the lead of Pontus Blomberg a... |
| 15.09.2022 | XNK Therapeutics appoints Dr. Anna-Karin Maltais as CSO | XNK Therapeutics appoints Dr. Anna-Karin Maltais as CSO
Thu, Sep 15, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Anna-Karin Maltais as Chief Scientific Officer, effective October 17t... |
| 01.09.2022 | XNK Therapeutics completes building phase of new GMP facility | XNK Therapeutics completes building phase of new GMP facility
Thu, Sep 01, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced the successful completion of the building phase of the company’s new GMP clean room fa... |
| 28.06.2022 | XNK broadens its pipeline with bladder cancer study | XNK broadens its pipeline with bladder cancer study
Tue, Jun 28, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced it is initiating a program targeting urothelial cancer, the most common form of bladder cancer. ... |
| 10.06.2022 | Positive clinical results of ACP-001 presented at EHA2022 | Positive clinical results of ACP-001 presented at EHA2022
Fri, Jun 10, 2022 16:30 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinical trial ACP-001 with ... |
| 09.05.2022 | Ted Fjällman new board member at XNK Therapeutics | Ted Fjällman new board member at XNK Therapeutics
Mon, May 09, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that Ted Fjällman, Partner at Flerie Invest, has joined the company’s board of directors.
Ted Fjäl... |
| 02.05.2022 | XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022 | XNK Therapeutics gets abstract on ACP-001 selected for presentation at EHA2022
Mon, May 02, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that an abstract on the long-term follow-up of the Phase I/II clinica... |
| 29.03.2022 | XNK Therapeutics raises SEK 132 million to accelerate growth | XNK Therapeutics raises SEK 132 million to accelerate growth
Tue, Mar 29, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced it has secured a private placement of SEK 132 million, to existing and new investors, l... |
| 23.03.2022 | XNK Therapeutics Reports First Patient Treated in Phase II Study in Multiple Myeloma | XNK Therapeutics Reports First Patient Treated in Phase II Study in Multiple Myeloma
Wed, Mar 23, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the first patient has been treated in a Phase II clinical ... |
| 22.02.2022 | XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23 | XNK Therapeutics to present at Redeye’s Regenerative Medicine/Cell Therapy event on February 23
Tue, Feb 22, 2022 08:05 CET Report this content
XNK Therapeutics AB’s CEO Johan Liwing will present at Redeye’s Regenerative Medicine/Cell Thera... |
| 17.02.2022 | Clinical study published regarding XNK Therapeutics’ NK cell-based product | Clinical study published regarding XNK Therapeutics’ NK cell-based product
Thu, Feb 17, 2022 08:05 CET Report this content
XNK Therapeutics AB (“XNK”) today announced that the first-in-human Phase I study ACP-001, performed at the Karolinsk... |
| 20.12.2021 | XNK Therapeutics strengthens its scientific network with two more advisors | XNK Therapeutics strengthens its scientific network with two more advisors Mon, Dec 20, 2021 08:10 CET
December 20th, 2021
XNK Therapeutics AB (“XNK”) today announced the appointment of Dr. Gunilla Enblad, Professor of oncology at Uppsala U... |
| 06.12.2021 | XNK Therapeutics announces study in acute myeloid leukemia (AML) patient samples | XNK Therapeutics announces study in acute myeloid leukemia (AML) patient samples Mon, Dec 06, 2021 08:10 CET
December 6th, 2021
XNK Therapeutics AB (“XNK”) today announced it will perform a proof of concept study in acute myeloid leukemia (... |
| 01.12.2021 | XNK Therapeutics to present at ABGSC Private Companies Seminar on December 6 | XNK Therapeutics to present at ABGSC Private Companies Seminar on December 6 Wed, Dec 01, 2021 08:05 CET
XNK Therapeutics AB’s CEO, Johan Liwing, will present at the ABGSC Private Companies event on December 6. The presentation starts at 09... |
| 16.11.2021 | XNK Therapeutics adds three scientific advisors to bolster platform technology | XNK Therapeutics adds three scientific advisors to bolster platform technology Tue, Nov 16, 2021 08:05 CET
XNK Therapeutics AB (“XNK”) today announced the strengthening of the company’s expertise by the appointment of Ola Landgren, M.D., Ph... |
| 29.09.2021 | XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy | XNK Therapeutics targets broader pipeline opportunities for its NK cell therapy Wed, Sep 29, 2021 08:05 CET
September 29, 2021
XNK Therapeutics AB (“XNK”) today announced plans to further expand the scope of its proprietary technology platf... |
| 15.09.2021 | Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics | Dr. David Berglund and Dr. Stephen Wooding nominated as new board members at XNK Therapeutics Wed, Sep 15, 2021 08:05 CET
XNK Therapeutics AB (“XNK”) today announced that Dr. David Berglund and Dr. Stephen Wooding are proposed to be appoint... |
| 03.09.2021 | XNK Therapeutics appoints Markus Thor as Chief Business Officer | XNK Therapeutics appoints Markus Thor as Chief Business Officer Fri, Sep 03, 2021 08:05 CET
Sept. 3, 2021
XNK Therapeutics AB (“XNK”) today announced the appointment of Markus Thor as Chief Business Officer, effective September 6th. He will... |
